CNSX:GSTR

Stock Analysis Report

Greenstar Biosciences

Executive Summary

Greenstar Biosciences Corp., a growth-oriented technology and services company, provides real estate, financial, management, intellectual property, and branding support to licensed cannabis businesses in the United States.


Snowflake Analysis

Adequate balance sheet and overvalued.

Share Price & News

How has Greenstar Biosciences's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: GSTR's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

0%

GSTR

-3.9%

CA Real Estate

-0.05%

CA Market


1 Year Return

n/a

GSTR

-11.8%

CA Real Estate

-24.6%

CA Market

Return vs Industry: Insufficient data to determine how GSTR performed against the Canadian Real Estate industry.

Return vs Market: Insufficient data to determine how GSTR performed against the Canadian Market.


Shareholder returns

GSTRIndustryMarket
7 Day0%-3.9%-0.05%
30 Day-50.0%-26.0%-21.2%
90 Day-50.0%-22.4%-24.7%
1 Yearn/a-10.4%-11.8%-22.1%-24.6%
3 Yearn/a7.7%1.5%-14.2%-22.1%
5 Yearn/a33.7%4.7%-1.9%-16.5%

Price Volatility Vs. Market

How volatile is Greenstar Biosciences's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Greenstar Biosciences undervalued compared to its fair value and its price relative to the market?

0.47x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate GSTR's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate GSTR's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: GSTR is unprofitable, so we can't compare its PE Ratio to the Real Estate industry average.

PE vs Market: GSTR is unprofitable, so we can't compare its PE Ratio to the Canadian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate GSTR's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: GSTR is good value based on its PB Ratio (0.5x) compared to the CA Real Estate industry average (0.6x).


Next Steps

Future Growth

How is Greenstar Biosciences forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

21.8%

Forecasted Real Estate industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Greenstar Biosciences has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Greenstar Biosciences performed over the past 5 years?

89.7%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: GSTR is currently unprofitable.

Growing Profit Margin: GSTR is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Unable to establish if GSTR's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.

Accelerating Growth: Unable to compare GSTR's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: GSTR is unprofitable, making it difficult to compare its past year earnings growth to the Real Estate industry (-22.9%).


Return on Equity

High ROE: GSTR has a negative Return on Equity (-15.03%), as it is currently unprofitable.


Next Steps

Financial Health

How is Greenstar Biosciences's financial position?


Financial Position Analysis

Short Term Liabilities: GSTR's short term assets (CA$1.7M) exceed its short term liabilities (CA$595.4K).

Long Term Liabilities: GSTR's short term assets (CA$1.7M) exceed its long term liabilities (CA$307.7K).


Debt to Equity History and Analysis

Debt Level: GSTR is debt free.

Reducing Debt: GSTR has not had any debt for past 5 years.


Balance Sheet

Inventory Level: GSTR has a low level of unsold assets or inventory.

Debt Coverage by Assets: GSTR's debt is not covered by short term assets (assets are -3.0070642798344E+16x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: GSTR has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: GSTR has less than a year of cash runway if free cash flow continues to grow at historical rates of 156.6% each year.


Next Steps

Dividend

What is Greenstar Biosciences's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate GSTR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate GSTR's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if GSTR's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if GSTR's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of GSTR's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

0.3yrs

Average management tenure


CEO

Tom Baird (58yo)

0.17

Tenure

Mr. Thomas Willison Baird, also known as Tom, has been Chief Executive Officer and Director at Greenstar Biosciences Corp. since February 2020. Mr. Baird has been the Chief Operating Officer at High Hampto ...


Leadership Team

NamePositionTenureCompensationOwnership
Thomas Baird
CEO & Director0.17yrno datano data
Brian Zasitko
Chief Financial Officer0.33yrno datano data
Daniel McAtee
Chief Operating Officer1.17yrsno data0.58% CA$15.4k

0.3yrs

Average Tenure

Experienced Management: GSTR's management team is not considered experienced ( 0.3 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Thomas Baird
CEO & Director0.17yrno datano data
Scott Reeves
Member of Strategic Advisory Board0.75yrno datano data
Rahim Rajwani
Chairman of Strategic Advisory Board0.17yrno datano data
Sean-Robbie Campbell
Member of Strategic Advisory Board0.75yrno datano data
Leighton Bocking
Director0.75yrno data0.075% CA$2.0k
Faizaan Lalani
Director0.92yrno datano data

0.8yrs

Average Tenure

47.5yo

Average Age

Experienced Board: GSTR's board of directors are not considered experienced ( 0.8 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: GSTR only recently listed within the past 12 months, with total shares outstanding growing by 74.1% in the past year..


Top Shareholders

Company Information

Greenstar Biosciences Corp.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Greenstar Biosciences Corp.
  • Ticker: GSTR
  • Exchange: CNSX
  • Founded:
  • Industry: Real Estate Operating Companies
  • Sector: Real Estate
  • Market Cap: CA$2.669m
  • Shares outstanding: 66.71m
  • Website: https://www.greenstarbiosciences.com

Location

  • Greenstar Biosciences Corp.
  • 422 Richards Street
  • Suite 170
  • Vancouver
  • British Columbia
  • V6B 2Z4
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
GSTRCNSX (Canadian National Stock Exchange)YesShare CapitalCACADJun 2019
GTSI.FOTCPK (Pink Sheets LLC)YesShare CapitalUSUSDJun 2019

Biography

Greenstar Biosciences Corp., a growth-oriented technology and services company, provides real estate, financial, management, intellectual property, and branding support to licensed cannabis businesses in the United States. The company is headquartered in Vancouver, Canada. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/04/03 05:15
End of Day Share Price2020/04/02 00:00
Earnings2019/11/30
Annual Earnings2019/08/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.